...
首页> 外文期刊>Expert opinion on drug safety >Cardiovascular and metabolic safety profiles of the fluoroquinolones.
【24h】

Cardiovascular and metabolic safety profiles of the fluoroquinolones.

机译:氟喹诺酮类药物的心血管和代谢安全性概况。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

INTRODUCTION: Certain fluoroquinolones share similar indications of use. A comparison among Cardiovascular and metabolic (i.e., dysglycemia) safety profiles of the fluoroquinolones might be particularly useful for the prescribers' decision-making process as well as to hypothesize future researcher purposes. AREAS COVERED: A literature search was conducted using keywords apt to identify information on safety profile of the fluoroquinolones. Publications concerned with descriptive and etiological surveys were manually reviewed. EXPERT OPINION: Cardiac alterations and blood glucose impairments might be associated with any fluoroquinolone. However, the benefit/risk profile of these agents could be stratified for the single compounds. Several predisposing factors, such as diabetes, heart illnesses and their related pharmacotherapies, might exacerbate the risk of potentially serious adverse events. In this context, the opportunity of the more appropriate choice among different fluoroquinolones could be applicable.
机译:简介:某些氟喹诺酮类药物具有相似的使用指征。氟喹诺酮类药物的心血管和代谢安全性(即血糖异常)之间的比较可能对开处方者的决策过程以及假设未来的研究者目的特别有用。覆盖区域:文献检索使用易于识别氟喹诺酮类药物安全性信息的关键字进行。有关描述性和病因学调查的出版物均经过人工审查。专家意见:心脏改变和血糖受损可能与任何氟喹诺酮有关。但是,对于单一化合物,可以对这些药物的获益/风险特征进行分层。某些易患因素,例如糖尿病,心脏病和相关的药物治疗,可能会加剧潜在的严重不良事件的风险。在这种情况下,可以应用在不同的氟喹诺酮类药物中进行更适当选择的机会。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号